Chugai Pharmaceutical Files New Drug Application for Anti-tumor Agent Bevacizumab.Tokyo, Japan, Apr 24, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Chugai Pharmaceutical has filed a new drug application (NDA (Non Disclosure Agreement) An agreement signed between two parties that have to disclose confidential information to each other in order to do business. In general, the NDA states why the information is being divulged and stipulates that it cannot be used for any ) for bevacizumab, its proprietary anti-tumor agent, with the Ministry of Health, Labor and Welfare. The company is seeking approval to use the agent for treating advanced or recurrent colorectal cancer colorectal cancer Malignant tumour of the large intestine (colon) or rectum. Risk factors include age (after age 50), family history of colorectal cancer, chronic inflammatory bowel diseases, benign polyps, physical inactivity, and a diet high in fat. . Bevacizumab, which is a humanized anti-VEFG monoclonal antibody, is currently marketed in the US and Europe under the trade name of Avastin. Following the request by the fifth Investigational Committee for Usage of Unapproved un·ap·proved adj. Not approved or sanctioned: an unapproved vaccine; an unapproved protest march. Drugs, the company has filed the NDA 18 months ahead of schedule. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion